# Intuitive Surgical Moat

Status: published. Policy: company-analysis-1.

The passages support a narrow installed-base advantage reinforced by repeat instrument and service demand and penalties for exiting fixed-payment leases. Growing procedures and recurring revenue demonstrate current customer engagement, but cancellable usage-based leases limit contractual protection. Realized revenue per procedure and system ASP benefited from product mix; broad pricing power and exceptional durability remain unproven.

## switching_costs

Fixed-payment lease exit penalties create demonstrated financial switching friction, while growing instrument, service and operating lease revenue supports an installed-base relationship with repeat demand. These disclosures support a bounded advantage rather than proof that customers cannot switch platforms.

Durability: Lease terms generally extend from 12 to 84 months, and non-cancellable operating lease payments totaled $1,100.9 million at December 31, 2025. Recurring revenue growth continued through June 2026. Protection beyond contractual terms is less established because renewal rates, retraining costs and competitive replacement outcomes are absent.

Risks: Customers can exit usage-based arrangements early, and utilization risk remains with Intuitive. Third parties already offer modified instruments extending labeled life. Named robotic competitors include both product introducers and prospective entrants, without company-specific competitive outcomes. Reimbursement limits, hospital purchasing pressure and service-related litigation could weaken monetization. Favorable product mix demonstrates realized revenue improvement but does not establish unrestricted repricing.

Invalidation: The advantage would be undermined by sustained declines in instrument and service demand per installed system, material usage-based cancellations or lease-asset losses, widespread replacement by competing platforms, or legal changes enabling third-party servicing and instruments that materially reduce repeat revenue. Continued growth driven solely by new placements while existing-customer utilization and renewals deteriorate would also contradict the dependency thesis.

Competitors: CMR Surgical Ltd., Distalmotion SA, Johnson & Johnson, Medtronic plc, Medicaroid Corporation, Noah Medical Corporation
- [https://www.sec.gov/Archives/edgar/data/1035267/000103526726000010/isrg-20251231.htm](https://www.sec.gov/Archives/edgar/data/1035267/000103526726000010/isrg-20251231.htm) · 2026-02-03
- [https://www.sec.gov/Archives/edgar/data/1035267/000103526726000058/isrg-20260630.htm](https://www.sec.gov/Archives/edgar/data/1035267/000103526726000058/isrg-20260630.htm) · 2026-07-21
- [https://www.sec.gov/Archives/edgar/data/1035267/000103526726000023/isrg-20260313.htm](https://www.sec.gov/Archives/edgar/data/1035267/000103526726000023/isrg-20260313.htm) · 2026-03-13
- [https://www.sec.gov/Archives/edgar/data/1035267/000103526725000017/isrg-20241231.htm](https://www.sec.gov/Archives/edgar/data/1035267/000103526725000017/isrg-20241231.htm) · 2025-01-31
- [https://www.sec.gov/Archives/edgar/data/1035267/000103526724000021/isrg-20231231.htm](https://www.sec.gov/Archives/edgar/data/1035267/000103526724000021/isrg-20231231.htm) · 2024-01-31
- [https://www.sec.gov/Archives/edgar/data/1035267/000103526726000032/isrg-20260331.htm](https://www.sec.gov/Archives/edgar/data/1035267/000103526726000032/isrg-20260331.htm) · 2026-04-22

[JSON](https://beanvest.com/stock/isrg/moat.json)